Challenge Your Exam Readiness With Our Free AOCNP Practice Questions

Male BRCA2 carriers have a substantially elevated risk of early-onset, clinically significant prostate cancer. Many expert groups recommend initiating annual PSA testing (with or without digital rectal exam) at age 40 with shared decision-making that covers benefits/harms, downstream biopsy pathways, and management options should an abnormal result occur. MRI is valuable for risk stratification and targeted biopsy after PSA elevation but is not a replacement for primary screening in asymptomatic men (Option C). Delaying until 55 or requiring symptoms (Options A/D) risks missing aggressive disease at a curable stage. The APRN should document family history, discuss lifestyle factors, explain PSA variability (infection, ejaculation), and establish a clear follow-up algorithm for abnormal results (repeat PSA, secondary tests like percent free PSA, MRI, urology referral). Provide education about cascade testing in relatives and coordinate broader BRCA-related risk management (male breast self-awareness, pancreatic screening in select families).